Sarcoidosis Associated Pulmonary Hypertension

Area of Science:

• Pulmonary Medicine
• Cardiology
• Rheumatology

Background:

• Sarcoidosis-associated pulmonary hypertension (SAPH) significantly increases morbidity and mortality in sarcoidosis patients.
• The prevalence of SAPH ranges from 2.9% to 20%, with multifactorial causes including lung disease, cardiac dysfunction, and extrinsic compression.
• Accurate early diagnosis of SAPH is hindered by limitations in current non-invasive screening strategies.

Purpose of the Study:

• To review the current understanding of sarcoidosis-associated pulmonary hypertension.
• To highlight diagnostic challenges and prognostic indicators for SAPH.
• To discuss current and potential future management strategies for SAPH.

Main Methods:

• Review of existing literature and registry outcomes.
• Analysis of factors contributing to SAPH development and prognosis.
• Evaluation of diagnostic tools, including transthoracic echocardiography and right heart catheterization.
• Assessment of treatment modalities and the role of lung transplantation.

Main Results:

• The 6-minute walk test (6MWT) demonstrates significant prognostic value in SAPH patients.
• Advanced lung disease, indicated by a reduced D_LCO (<35% predicted), correlates with reduced transplant-free survival in pre-capillary SAPH.
• Transthoracic echocardiography is the recommended screening tool for right heart catheterization (RHC) in suspected SAPH.

Conclusions:

• Effective management of SAPH requires addressing underlying mechanisms, with pulmonary vasodilators beneficial in specific phenotypes.
• Lung transplantation is a high-risk option for end-stage SAPH.
• Further multi-centered randomized controlled trials are essential to advance SAPH therapies and improve patient outcomes.